← Back to Analyst Consensus 
SPRY Buy
ARS Pharmaceuticals, Inc.
Current Price —
Implied Upside —
Analysts 10
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 17, 2026 (22 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Aug 13, 2026 | Leerink Partners | maintain | Outperform → Outperform | — | 51% |
| Jun 25, 2026 | Leerink Partners | maintain | Outperform → Outperform | — | 51% |
| May 28, 2026 | Cantor Fitzgerald | maintain | Overweight → Overweight | — | 50% |
| Sep 4, 2025 | Roth Capital | initiate | — → Buy | $40 | 53% |
| Mar 7, 2025 | Scotiabank | initiate | — → Sector Outperform | $30 | 55% |
| Jan 14, 2025 | Raymond James | maintain | Strong Buy → Strong Buy | $28 | 54% |
| Jan 13, 2025 | Leerink Partners | maintain | Outperform → Outperform | $27 | 51% |
| Oct 8, 2024 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $30 | 50% |
| Sep 20, 2024 | Leerink Partners | maintain | Outperform → Outperform | $25 | 51% |
| Sep 16, 2024 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $30 | 50% |
| Sep 9, 2024 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $30 | 50% |
| Aug 20, 2024 | Cantor Fitzgerald | initiate | — → Overweight | $30 | 50% |
| Aug 13, 2024 | Raymond James | upgrade | Outperform → Strong Buy | $22 | 54% |
| Jul 25, 2024 | Raymond James | initiate | — → Outperform | $18 | 54% |
| Mar 11, 2024 | Wedbush | reiterate | Outperform → Outperform | $19 | 58% |
| Mar 5, 2024 | Leerink Partners | upgrade | Market Perform → Outperform | $18 | 51% |
| Nov 13, 2023 | Wedbush | maintain | Outperform → Outperform | $13 | 58% |
| Sep 21, 2023 | Wedbush | maintain | Outperform → Outperform | $5 | 58% |
| Sep 20, 2023 | William Blair | downgrade | Outperform → Market Perform | $0 | 48% |
| Aug 14, 2023 | Wedbush | reiterate | Outperform → Outperform | $15 | 58% |
| Jun 21, 2023 | Wedbush | maintain | Outperform → Outperform | $15 | 58% |
| May 18, 2023 | Wedbush | reiterate | Outperform → Outperform | $17 | 58% |
| May 12, 2023 | Wedbush | reiterate | Outperform → Outperform | $17 | 58% |
| May 10, 2023 | Wedbush | reiterate | — → Outperform | $17 | 58% |
| Jan 31, 2023 | Wedbush | initiate | — → Outperform | $10 | 58% |
| Jan 4, 2023 | William Blair | initiate | — → Outperform | $0 | 48% |
| Dec 13, 2022 | SVB Leerink | initiate | — → Outperform | $14 | — |
Price Target Trend
Apr 27, 2026 Oct 26, 2026
EPS Estimates
+1q —
0y —
0q —
+1y —
Cross-Platform Signals
No cross-platform signals in the last 90 days